ReviewJournal of experimental pharmacology2021
Experimental Therapeutic Solutions for Behcet's Disease.
Review in Journal of experimental pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Research progress on the role of IL‑37 in gynecological and obstetrics‑related diseases (Review).International journal of molecular medicine · 2026Review
- Evaluation of predictors and clinical outcome after tapering of chronic systemic corticosteroids in Behçet's disease patients.Clinical rheumatology · 2026Observational
- Severe aortic regurgitation with acute decompensation as initial presentation of Behçet's syndrome: a case report.European heart journal. Case reports · 2025Article
- Behçet's disease: incidence, prevalence, and real-word data on the use of biologic agents in Japan.Journal of gastroenterology · 2025Observational
- Assessment of IL-6 Pathway Inhibition in Gastrointestinal Behçet's Disease from Immunological and Clinical Perspectives.Biomedicines · 2025Review
- The clinical manifestations and treatment outcomes of Behçet's disease: A single-center experience.Health science reports · 2024Article
- Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive Strategies.Medical science monitor : international medical journal of experimental and clinical research · 2024Review
- Pseudotumoral neuro-behcet's disease: case series and review of literature.Acta neurologica Belgica · 2024Review
- Behcet's disease: Diagnosed as isolated recurrent oral aphthae; a case report.Annals of medicine and surgery (2012) · 2022Article
- The association between vitamin D levels and oxidative stress markers in Egyptian Behcet's disease patients.Orphanet journal of rare diseases · 2022Article
- Mucocutaneous manifestations of Behçet's disease: Pathogenesis and management from perspectives of vasculitis.Frontiers in medicine · 2022Review
- Case report and analysis: Behçet's disease with lower extremity vein thrombosis and pseudoaneurysm.Frontiers in immunology · 2022Article
- Pathergy test with a 23G needle with and without self-saliva in patients with Behçet's disease, recurrent aphthous stomatitis and control group compared to the 20G test.Reumatologia · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Behcet's disease (BD) is a chronic systemic vasculitis with inflammation attacks that involve multiple organs. In addition to numerous mucocutaneous symptoms, notably recurrent oral and genital ulcers, ocular, articular, vascular, gastrointestinal, cardiac, and neurological system involvement can be observed. Mucocutaneous lesions are the primary symptom of the disease in most patients, and they usually occur before major organ involvement and other symptoms of the disease. Recognizing the disease's mucocutaneous lesions is very important to diagnose at an early stage, control with appropriate treatment and close follow-up, and prevent major organ involvement. Genome-wide association studies (GWAS) in recent years have confirmed that HLA-B*51 is the most significant genetic predisposing factor. The majority of gene polymorphisms have been detected in molecules that respond to microorganisms and genes encoding cytokines and adhesion molecules. The infectious agent
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.